Healthcare
Cogstate Limited(COGZF)
Live Price
Offline$1.89
+0.00% today
1Y Change
+96.88%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $290.00M
- Revenue Growth
- -22.0%
- EPS Growth
- +23.3%
- Dividend Yield
- 0.9%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cogstate Limited (COGZF) is a Healthcare stock with a market cap of $290.00M and listed on OTC. The stock last traded around $1.89 and up 96.9% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -22.0%, EPS growth of +23.3%, a dividend yield of 0.9%. What stands out right now is revenue -22.0%, EPS +23.3%, free cash flow +115.6% with operating margin 22.7% and ROIC 22.4%. The dividend is present but secondary, with a yield around 0.9%. Valuation is more restrained than many high-expectation growth names at P/E 19.8 and price/sales 4.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines COGZF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-22.0% vs +7.6% peer median
Operating Margin
Above sector median
+22.7% vs +19.4% peer median
P/E
Below sector median
19.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Feb 18, 2026 with an EPS surprise of +21.9% and a revenue surprise of +0.1%.
The operating picture looks softer than before
Revenue is at -22.0% and EPS is at +23.3%, with operating margin around 22.7%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 18, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +14.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 18, 2026 | +21.9% | +0.0% | +0.0% | +2.6% |
2025 Aug 17, 2025 | โ | +0.0% | +17.0% | +20.0% |
2025 Feb 20, 2025 | โ | +1.0% | +25.0% | +19.8% |
Benchmark Edge
COGZF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
COGZF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
COGZF Max Drawdown
-35.24%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for COGZF and SPY.
Company Overview
Cogstate Limited
OTC
Cogstate Limited is a neuroscience technology company specializing in the creation, validation, and commercialization of digital brain health assessments for use in academic and industry-sponsored research worldwide. It offers cognitive services including project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. The company designs and provides quality assurance services for clinical trials, focusing on the administration, scoring, and recording of conventional brain health assessments. Its technology and services quantify the effects of diseases, drugs, devices, and other interventions on human subjects in clinical trials primarily conducted by pharmaceutical and biotechnology companies. Additionally, Cogstate Limited provides Cognigram, a computerized test aiding healthcare professionals in detecting cognitive decline, along with valid, reliable, and sensitive digital cognitive tests and electronic clinical outcome assessment solutions. It supports endpoint data quality assurance through tailored rater training and strategic central monitoring programs combining operational approaches, advanced analytics, and scientific expertise. Founded in 1999 and headquartered in Melbourne, Australia, Cogstate Limited plays a key role in optimizing cognitive measurements for clinical research and brain health insights.
- Leadership
- Mr. Bradley John O'Connor B.Bus, C.A.
- Employees
- 160
- Street Address
- 367 Collins Street, Level 32
- Mailing
- Melbourne, VIC, 3000
- Region
- Melbourne, VIC, Australia
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 19.8
- EV/EBITDA
- 13.4
- Price/Sales
- 4.0
- Price/Book
- 5.5
Growth
- Revenue
- -22.0%
- EPS
- +23.3%
- Free Cash Flow
- +115.6%
Profitability
- Gross Margin
- 36.1%
- Operating Margin
- 22.7%
- Net Margin
- 20.0%
- ROE
- 29.1%
- ROIC
- 22.4%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 3.96
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.